Tideglusib

Tideglusib (NP-12, NP031112) is a potent and irreversible^[1] small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.^[2]

Tideglusib

Identifiers
IUPAC name 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
CAS Number	865854-05-3
PubChem CID	11313622
ChemSpider	9488589
UNII	Q747Y6TT42
ChEBI	CHEBI:147398
CompTox Dashboard (EPA)	DTXSID90235682
Chemical and physical data
Formula	C19H14N2O2S
Molar mass	334.39 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C3SN(c1cccc2c1cccc2)C(=O)N3Cc4ccccc4
InChI InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2

Clinical trials

Tideglusib has been evaluated in clinical trials for:

• Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 (PSP) and 2012 (Alzheimer's disease) due to lack of efficacy^{[3] [4][5][6][1]}
• Congenital/juvenile-onset myotonic muscular dystrophy type I.^[7]

Research

Tideglusib is or has been under investigation for multiple applications:

• Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.^[8][9]
• Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis.^[10][11]
• Arrhythmogenic Right Ventricular Cardiomyopathy as of 2025.^[12]